

Modified Form PTO-1499	Atty. Docket No. A-451M	Serial No. 09/211,297
<b>LIST OF REFERENCES CITED BY APPLICANT</b>	Applicant Boyle	
(Use several sheets if necessary)	Filing Date December 14, 1998	Group
Filed: 4/20/10		

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
/MS/	A1	6,479,635 B1	2002-11-12	Anderson			
	A2	6,838,262 B1	2005-01-04	Anderson			
	A3	7,411,050 B2	2008-08-12	Anderson			
	A4	7,449,185 B2	2008-11-08	Yamaguchi et al.			
	A5	7,527,790 B2	2009-05-05	Yamaguchi et al.			
	A6	2005/0003391 A1	2005-01-06	Anderson			
	A7	2005/0003400 A1	2005-01-06	Boyle			
	A8	2005/0208580 A1	2005-01-22	Yamaguchi et al.			
	A9	2006/0246064 A1	2006-11-02	Boyle			
	A10	2007/0009520 A1	2007-01-11	Yamaguchi et al.			
	A11	2008/0009014 A1	2008-01-10	Anderson			
	A12	2008/0187540 A9	2008-08-07	Yamaguchi et al.			
	A13	2009/0004196 A1	2009-01-01	Anderson			
	A14	2009/0017033 A1	2009-01-15	Anderson			
/MS/	A15	11/595,524	2006-11-09	Choi et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
/MS/	B1	0 784 093 A1	1997-07-16	EP			
	B2						
	B3						
	B4						

## OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

/MS/	C1	Bharti and Aggarwal, "Ranking the role of RANK ligand in apoptosis", Apoptosis, 9: 677-690 (2004)
/MS/	C2	Chopin et al., "Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21 waf1", Exp. Cell Res., 298: 560-573 (2004)
/MS/	C3	Collin et al., "Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxyvitamin D3", Endocrinology, 131(3): 1181-1187 (1992)

EXAMINER:	/Michael Sziperka/	Date Considered:	04/29/2010
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Modified Form PTO-1449	Atty. Docket No. <b>A-451M</b>	Serial No. <b>09/211,297</b>
<b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Applicant <b>Boyle</b>	
	Filing Date <b>December 14, 1998</b>	Group
Filed: 4/20/10		

/MS/	C4	Lacey et al., "Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages", <i>Endocrinology</i> , 136(8): 2367-2376 (1995)
	C5	Roitt et al., <i>Immunology</i> , 3rd Ed., MOSBY, ISBN: 0-397-44765-5, (1993)
	C6	Takahashi et al., "Osteoblastic cells are involved in osteoclast formation", <i>Endocrinology</i> , 123(5): 2600-2602 (1996)
	C7	Theilli et al., "RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution", <i>Annu. Rev. Immunol.</i> , 20: 795-823 (2002)
	C8	Yasuda et al., "Identify of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro", <i>Endocrinology</i> , 139(3): 1329-1337 (1998)
	C9	Office Communication mailed March 30, 2009 for USSN 11/595,524
	C10	Amendment in Response to Office Action mailed March 30, 2009, filed on September 29, 2009 for USSN 11/595,524
/MS/	C11	Office Communication mailed January 21, 2010 for USSN 11/595,524

EXAMINER: <b>/Michael Szerka/</b>	Date Considered: <b>04/29/2010</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	